Emmecell Announces Closing of Strategic Financing
· financialcontent
AI Briefing
- • Emmecell closes strategic financing round with existing investors and Bausch + Lomb.
- • Financing aims to support development of magnetic cell delivery technologies.
- • Bausch + Lomb joins existing investors in Emmecell's financing round.
Context
Emmecell, a clinical-stage biotechnology company, has closed a strategic financing round. The company is developing magnetic cell delivery technologies for ophthalmic diseases. Existing investors and Bausch + Lomb participated in the financing.
The financing round is a significant development for Emmecell as it received support from both existing investors and a strategic industry participant. Bausch + Lomb's participation is also a key aspect of the financing round.
Advertisement